TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02824861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bemobile

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bemobile
Study: NCT02286089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpRegen
Description: Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
Study: NCT02789579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
Study: NCT04556825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: After the arthroscopic operation was completed, a local PRP with 4ml was injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
Study: NCT01391949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detailed feedback
Description: Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic feedback
Description: Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
Study: NCT04803903

Intervention type: DEVICE
Intervention: Flotraq Sensor with EV1000 incorporating the HPI algorithm
Description: The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension.
Study: NCT02322515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention taping
Description: A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
Study: NCT00982696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opioid Growth Factor
Description: 250ug per kilogram weekly IV infusions
Study: NCT02322515

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Taping
Description: A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
Study: NCT04193527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaTSCAN™ Ioflupane (123I) Injection
Description: All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
Study: NCT03856177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Induction
Description: Described in arm
Study: NCT03069963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z0063
Description: Pharmaceutical form: chewable tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z0063
Description: Pharmaceutical form: chewable tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaviscon
Description: Pharmaceutical form: chewable tablets~Route of administration: oral
Study: NCT02449928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium lactate Ringer's injection(Baxter, ShangHai, China)
Description: use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
Study: NCT01425866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured self-management group education during 2 years
Description: After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured self-management group education during 2 years
Description: After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
Study: NCT03977532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-blood sampling
Description: capillary sampling of 40 microliters performed at the fingertip
Study: NCT02449928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)
Description: use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
Study: NCT03069963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaviscon
Description: Pharmaceutical form: chewable tablets~Route of administration: oral
Study: NCT00644137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Help stop smoking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Help stop smoking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarettes
Description: help stop smoking with study medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarettes
Description: help stop smoking with study medication
Study: NCT01811953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: medium dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: low dose of Empagliflozin oral administration
Study: NCT01002391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduction mammaplasty
Description: Dressing following reduction mammaplasty is removed on the first postoperative day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduction mammaplasty
Description: Dressing following reduction mammaplasty is removed on the sixth postoperative day
Study: NCT01811953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin
Description: low dose of Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral administration
Study: NCT01276418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Ablation and coagulation of soft tissue
Study: NCT01811953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin
Description: medium dose of Empagliflozin oral administration
Study: NCT01815203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo with subsequent cognitive tasks and food test.
Study: NCT04184258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pooled mesenchymal stem cell
Description: Pooled allogenic mesenchymal stem cell derived from olfactory mucosa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
Study: NCT02836743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Slow-release melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Slow-release melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01481129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01528423

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
Study: NCT02097836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Training
Description: Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
Study: NCT03848520

Intervention type: PROCEDURE
Intervention: TKA
Description: TKA performed in the past
Study: NCT01411410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
Study: NCT04214795

Intervention type: OTHER
Intervention: Observational study. Postnatal variables are recorded
Description: Postnatal evolution is analyzed in both groups

Intervention type: OTHER
Intervention: Observational study. Postnatal variables are recorded
Description: Postnatal evolution is analyzed in both groups
Study: NCT02494908

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playing a computer game simulating a car race
Description: Playing a computer game simulating a car race

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playing a computer game simulating a car race
Description: Playing a computer game simulating a car race
Study: NCT02721004

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
Study: NCT00686205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collection of follow-up sample based on PRISM HIV O Plus result
Description: Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
Study: NCT02475460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Less Invasive Surgery (LIS)
Description: Less invasive HM 3 LVAD surgical implant procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3™
Description: HM 3 LIS
Study: NCT00898053

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01583647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: 1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: 2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
Study: NCT02764619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03002493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
Study: NCT03499054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
Study: NCT01528423

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device

Intervention type: PROCEDURE
Intervention: XtremeCT
Description: The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
Study: NCT03076229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Marriage Program
Description: Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Marriage Program
Description: Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
Study: NCT00636701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
Study: NCT04095533

Intervention type: OTHER
Intervention: Tibialis anterior muscle cross-sectional area assessment by ultrasound
Description: Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg.
Study: NCT04875078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA-1 Phototherapy
Description: UVA-1 Phototherapy treatments
Study: NCT03589729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV